Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

吡格列酮 阿格列汀 二甲双胍 耐受性 2型糖尿病 医学 内科学 血糖性 内分泌学 糖尿病 临床终点 安慰剂 胰岛素 药理学 胃肠病学 泌尿科 随机对照试验 磷酸西他列汀 不利影响 替代医学 病理
作者
Ralph A. DeFronzo,Charles Burant,P. Fleck,Candy Wilson,Qais Mekki,Richard E. Pratley
出处
期刊:The Journal of Clinical Endocrinology and Metabolism [Oxford University Press]
卷期号:97 (5): 1615-1622 被引量:96
标识
DOI:10.1210/jc.2011-2243
摘要

Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control. The aim of the study was to assess the efficacy and tolerability of alogliptin combined with pioglitazone in metformin-treated type 2 diabetic patients. We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-arm study in patients with type 2 diabetes. The study consisted of 26-wk treatment with alogliptin (12.5 or 25 mg qd) alone or combined with pioglitazone (15, 30, or 45 mg qd) in 1554 patients on stable-dose metformin monotherapy (≥1500 mg) with inadequate glycemic control. The primary endpoint was change in glycosylated hemoglobin (HbA1c) from baseline to wk 26. Secondary endpoints included changes in fasting plasma glucose and β-cell function. Primary analyses compared pioglitazone therapy [all doses pooled, pioglitazone alone (Pio alone); n = 387] with alogliptin 12.5 mg plus any dose of pioglitazone (A12.5+P; n = 390) or alogliptin 25 mg plus any dose of pioglitazone (A25+P; n = 390). When added to metformin, the least squares mean change (LSMΔ) from baseline HbA1c was −0.9 ± 0.05% in the Pio-alone group and −1.4 ± 0.05% in both the A12.5+P and A25+P groups (P < 0.001 for both comparisons). A12.5+P and A25+P produced greater reductions in fasting plasma glucose (LSMΔ = −2.5 ± 0.1 mmol/liter for both) than Pio alone (LSMΔ = −1.6 ± 0.1 mmol/liter; P < 0.001). A12.5+P and A25+P significantly improved measures of β-cell function (proinsulin:insulin and homeostasis model assessment of β-cell function) compared to Pio alone, but had no effect on homeostasis model assessment of insulin resistance. The LSMΔ body weight was 1.8 ± 0.2, 1.9 ± 0.2, and 1.5 ± 0.2 kg in A12.5+P, A25+P, and Pio-alone groups, respectively. Hypoglycemia was reported by 1.0, 1.5, and 2.1% of patients in the A12.5+P, A25+P, and Pio-alone groups, respectively. In type 2 diabetic patients inadequately controlled by metformin, the reduction in HbA1c by alogliptin and pioglitazone was additive. The decreases in HbA1c with A12.5+P and A25+P were similar. All treatments were well tolerated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飞云发布了新的文献求助10
刚刚
X欣完成签到,获得积分10
刚刚
刚刚
刚刚
在水一方应助留白采纳,获得10
1秒前
1秒前
hhh完成签到,获得积分10
1秒前
3秒前
3秒前
3秒前
BY0131发布了新的文献求助10
4秒前
4秒前
Hello应助天边采纳,获得10
4秒前
PengHu发布了新的文献求助10
5秒前
情怀应助Rason采纳,获得10
6秒前
量子星尘发布了新的文献求助30
6秒前
7秒前
冯诗樱发布了新的文献求助20
8秒前
8秒前
曦小蕊发布了新的文献求助10
8秒前
wjx发布了新的文献求助10
9秒前
10秒前
10秒前
Emmmm完成签到,获得积分10
10秒前
LLLLL发布了新的文献求助10
11秒前
12秒前
刘萄发布了新的文献求助10
12秒前
小王完成签到,获得积分10
12秒前
香蕉觅云应助Even采纳,获得10
12秒前
12秒前
典雅碧空发布了新的文献求助10
13秒前
ZZ发布了新的文献求助10
14秒前
火柴发布了新的文献求助10
14秒前
15秒前
BY0131完成签到,获得积分20
15秒前
hhj完成签到,获得积分10
15秒前
允柠关注了科研通微信公众号
15秒前
PengHu完成签到,获得积分10
16秒前
千万雷同发布了新的文献求助10
16秒前
留白发布了新的文献求助10
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974882
求助须知:如何正确求助?哪些是违规求助? 3519431
关于积分的说明 11198315
捐赠科研通 3255698
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877237
科研通“疑难数据库(出版商)”最低求助积分说明 806219